These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19248829)

  • 1. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension.
    Castro MM; Rizzi E; Rodrigues GJ; Ceron CS; Bendhack LM; Gerlach RF; Tanus-Santos JE
    Free Radic Biol Med; 2009 May; 46(9):1298-307. PubMed ID: 19248829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats.
    Martinez ML; Castro MM; Rizzi E; Fernandes K; Demacq C; Bendhack LM; Gerlach RF; Tanus-Santos JE
    Eur J Pharmacol; 2008 Sep; 591(1-3):224-30. PubMed ID: 18634778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats.
    Castro MM; Rizzi E; Figueiredo-Lopes L; Fernandes K; Bendhack LM; Pitol DL; Gerlach RF; Tanus-Santos JE
    Atherosclerosis; 2008 Jun; 198(2):320-31. PubMed ID: 18054360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time course involvement of matrix metalloproteinases in the vascular alterations of renovascular hypertension.
    Ceron CS; Rizzi E; Guimaraes DA; Martins-Oliveira A; Cau SB; Ramos J; Gerlach RF; Tanus-Santos JE
    Matrix Biol; 2012 May; 31(4):261-70. PubMed ID: 22342460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling.
    Castro MM; Rizzi E; Prado CM; Rossi MA; Tanus-Santos JE; Gerlach RF
    Matrix Biol; 2010 Apr; 29(3):194-201. PubMed ID: 19969080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats.
    Martinez ML; Rizzi E; Castro MM; Fernandes K; Bendhack LM; Gerlach RF; Tanus-Santos JE
    Eur J Pharmacol; 2008 Dec; 599(1-3):110-6. PubMed ID: 18930722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability.
    Castro MM; Rizzi E; Ceron CS; Guimaraes DA; Rodrigues GJ; Bendhack LM; Gerlach RF; Tanus-Santos JE
    Nitric Oxide; 2012 Mar; 26(3):162-8. PubMed ID: 22327038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress contributes to renovascular hypertension.
    Oliveira-Sales EB; Dugaich AP; Carillo BA; Abreu NP; Boim MA; Martins PJ; D'Almeida V; Dolnikoff MS; Bergamaschi CT; Campos RR
    Am J Hypertens; 2008 Jan; 21(1):98-104. PubMed ID: 18091751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase (MMP)-2 activation by oxidative stress decreases aortic calponin-1 levels during hypertrophic remodeling in early hypertension.
    Blascke de Mello MM; Parente JM; Schulz R; Castro MM
    Vascul Pharmacol; 2019 May; 116():36-44. PubMed ID: 30339939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antioxidant treatment with tempol and apocynin prevents endothelial dysfunction and development of renovascular hypertension.
    Costa CA; Amaral TA; Carvalho LC; Ognibene DT; da Silva AF; Moss MB; Valença SS; de Moura RS; Resende AC
    Am J Hypertens; 2009 Dec; 22(12):1242-9. PubMed ID: 19779472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system.
    Iglarz M; Touyz RM; Viel EC; Amiri F; Schiffrin EL
    Am J Hypertens; 2004 Jul; 17(7):597-603. PubMed ID: 15243979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tempol inhibits TGF-β and MMPs upregulation and prevents cardiac hypertensive changes.
    Rizzi E; Castro MM; Ceron CS; Neto-Neves EM; Prado CM; Rossi MA; Tanus-Santos JE; Gerlach RF
    Int J Cardiol; 2013 Apr; 165(1):165-73. PubMed ID: 21917342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension.
    Ceron CS; Castro MM; Rizzi E; Montenegro MF; Fontana V; Salgado MC; Gerlach RF; Tanus-Santos JE
    Br J Pharmacol; 2010 May; 160(1):77-87. PubMed ID: 20331602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension.
    Marçal DM; Rizzi E; Martins-Oliveira A; Ceron CS; Guimaraes DA; Gerlach RF; Tanus-Santos JE
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Jan; 383(1):35-44. PubMed ID: 21058008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal changes in cardiac matrix metalloproteinase activity, oxidative stress, and TGF-β in renovascular hypertension-induced cardiac hypertrophy.
    Rizzi E; Ceron CS; Guimaraes DA; Prado CM; Rossi MA; Gerlach RF; Tanus-Santos JE
    Exp Mol Pathol; 2013 Feb; 94(1):1-9. PubMed ID: 23073243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β1-Adrenergic blockers exert antioxidant effects, reduce matrix metalloproteinase activity, and improve renovascular hypertension-induced cardiac hypertrophy.
    Rizzi E; Guimaraes DA; Ceron CS; Prado CM; Pinheiro LC; Martins-Oliveira A; Gerlach RF; Tanus-Santos JE
    Free Radic Biol Med; 2014 Aug; 73():308-17. PubMed ID: 24933619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxycycline dose-dependently inhibits MMP-2-mediated vascular changes in 2K1C hypertension.
    Guimaraes DA; Rizzi E; Ceron CS; Oliveira AM; Oliveira DM; Castro MM; Tirapelli CR; Gerlach RF; Tanus-Santos JE
    Basic Clin Pharmacol Toxicol; 2011 May; 108(5):318-25. PubMed ID: 21176109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-β and MMPs, and decreases vascular remodeling in renovascular hypertension.
    Ceron CS; Rizzi E; Guimarães DA; Martins-Oliveira A; Gerlach RF; Tanus-Santos JE
    Free Radic Biol Med; 2013 Dec; 65():47-56. PubMed ID: 23806385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antioxidant tempol prevents and partially reverses dexamethasone-induced hypertension in the rat.
    Zhang Y; Croft KD; Mori TA; Schyvens CG; McKenzie KU; Whitworth JA
    Am J Hypertens; 2004 Mar; 17(3):260-5. PubMed ID: 15001201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ca2+-activated K+ channels underlying the impaired acetylcholine-induced vasodilation in 2K-1C hypertensive rats.
    Callera GE; Yogi A; Tostes RC; Rossoni LV; Bendhack LM
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1036-42. PubMed ID: 14978190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.